Subsequent Events

3 Months Ended

Mar. 31, 2022

Subsequent Events [Abstract]

Subsequent Events

Note 14 – Subsequent Events

The Company has evaluated events subsequent to March 31, 2022 for potential recognition or disclosure in its condensed consolidated financial statements. There have been no material subsequent events requiring recognition or disclosure in this Quarterly Report on Form 10-Q, other than noted below.

On April 6, 2022, we announced that we are part of a partnership that has acquired two pharmaceutical plants in St. Louis, Missouri.

On May 5, 2022, the Company's Board of Directors authorized the repurchase of up to $4.0 million of the Company's outstanding shares of common stock over a three-year period following the effective date of the share repurchase program (“2022 Repurchase Program”). The timing and actual number of shares repurchased will depend on a variety of factors, including price, general business and market conditions, and the existence of opportunities in the Company’s business.